Business Description
Piramal Pharma Ltd
ISIN : INE0DK501011
Total Employee Number:
5,476Compare
Compare
Traded in other countries / regions
543635.India Index Membership
NIFTY 500 IPO Date
2022-10-19Description
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of pharma products across a domestic and international distribution network. It operates under three business verticals: i) Piramal Pharma Solutions: It is an Integrated Contract Development and Manufacturing Organization (CDMO): API and Formulations, ii) Piramal Critical Care (PCC), Complex Hospital Generics (CHG): Inhalation Anesthesia, Injectable Anesthesia and PainManagement, Intrathecal Therapy and other products, and iii) Piramal Consumer Healthcare (PCH) business, selling OTC brands. The majority of the company's revenue is derived from the sale of Pharmaceuticals, mainly Inhalation Anesthesia in the export markets, including the USA, Europe, Japan, and others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.24 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.7 | |||||
Debt-to-EBITDA | 5.7 | |||||
Interest Coverage | 0.27 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 2.18 | |||||
Beneish M-Score | -3.13 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.3 | |||||
3-Year EBITDA Growth Rate | 0.4 | |||||
3-Year EPS without NRI Growth Rate | 2.8 | |||||
3-Year Book Growth Rate | 3.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.13 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.05 | |||||
9-Day RSI | 51.09 | |||||
14-Day RSI | 52.02 | |||||
3-1 Month Momentum % | 12.59 | |||||
6-1 Month Momentum % | -0.49 | |||||
12-1 Month Momentum % | -22.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.51 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.28 | |||||
Days Inventory | 305.05 | |||||
Days Sales Outstanding | 89.05 | |||||
Days Payable | 219.44 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.08 | |||||
Forward Dividend Yield % | 0.08 | |||||
5-Year Yield-on-Cost % | 0.08 | |||||
3-Year Average Share Buyback Ratio | -2.9 | |||||
Shareholder Yield % | -1.81 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.49 | |||||
Operating Margin % | 1.02 | |||||
Net Margin % | -3.68 | |||||
EBITDA Margin % | 11.23 | |||||
FCF Margin % | 8.6 | |||||
OCF Margin % | 18.63 | |||||
ROE % | -4.01 | |||||
ROA % | -1.96 | |||||
ROIC % | 0.66 | |||||
3-Year ROIIC % | 16.09 | |||||
ROC (Joel Greenblatt) % | 2.09 | |||||
ROCE % | 1.33 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 109.79 | |||||
Price-to-Owner-Earnings | 46.07 | |||||
PS Ratio | 2.53 | |||||
PB Ratio | 2.78 | |||||
Price-to-Tangible-Book | 5.65 | |||||
Price-to-Free-Cash-Flow | 29.96 | |||||
Price-to-Operating-Cash-Flow | 13.84 | |||||
EV-to-EBIT | 164.67 | |||||
EV-to-EBITDA | 27.23 | |||||
EV-to-Revenue | 3.06 | |||||
EV-to-FCF | 36.51 | |||||
Price-to-GF-Value | 0.98 | |||||
Earnings Yield (Greenblatt) % | 0.61 | |||||
FCF Yield % | 3.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Piramal Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 88,690.7 | ||
| EPS (TTM) (₹) | -2.47 | ||
| Beta | 1.3043 | ||
| 3-Year Sharpe Ratio | 0.57 | ||
| 3-Year Sortino Ratio | 1 | ||
| Volatility % | 30.24 | ||
| 14-Day RSI | 52.02 | ||
| 14-Day ATR (₹) | 6.236255 | ||
| 20-Day SMA (₹) | 169.475 | ||
| 12-1 Month Momentum % | -22.67 | ||
| 52-Week Range (₹) | 132.3 - 220.85 | ||
| Shares Outstanding (Mil) | 1,326.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Piramal Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Piramal Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| INR 0.140000 Cash Dividend | 2025-07-16 | 216.22 (+3.50%) |
Show
Entries
Piramal Pharma Ltd Frequently Asked Questions
What is Piramal Pharma Ltd(NSE:PPLPHARMA)'s stock price today?
The current price of NSE:PPLPHARMA is ₹171.66. The 52 week high of NSE:PPLPHARMA is ₹220.85 and 52 week low is ₹132.30.
When is next earnings date of Piramal Pharma Ltd(NSE:PPLPHARMA)?
The next earnings date of Piramal Pharma Ltd(NSE:PPLPHARMA) is .
Does Piramal Pharma Ltd(NSE:PPLPHARMA) pay dividends? If so, how much?
The Dividend Yield %  of Piramal Pharma Ltd(NSE:PPLPHARMA) is 0.08% (As of Today), Highest Dividend Payout Ratio of Piramal Pharma Ltd(NSE:PPLPHARMA) was 0.12. The lowest was 0.12. And the median was 0.12. The  Forward Dividend Yield % of Piramal Pharma Ltd(NSE:PPLPHARMA) is 0.08%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Piramal Pharma Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers